{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:00:58Z","timestamp":1775833258751,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To investigate the effect of multiple intravitreal injections of conbercept on the cornea in patients with branch retinal vein occlusion (BRVO)-induced macular edema.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The retrospective study analyzed the clinical data of 40 patients (40 eyes) with BRVO-induced macular edema between March 2020 and March 2023. All patients received intravitreal injections of conbercept according to the \u201c3 + PRN\u201d regimen and were followed for at least 6 months. Corneal analysis was performed using a corneal endothelial microscope and a Pentacam corneal topographic map. The best-corrected vision acuity (BCVA), central retinal thickness, central corneal thickness, corneal endothelial cell density, hexagonal cell percentage, and coefficient of variation before and at 1, 3, and 6 months after the injection were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 40 patients (22 males and 18 females) with an average age of 50.80 \u00b1 7.35 years (range, 38\u201367 years). The corneal endothelial cell densities, central corneal thicknesses, hexagonal cell percentages, and coefficients of variation before and at 1, 3, and 6 months after the injection were not significantly different (<jats:italic>P<\/jats:italic> &amp;gt; 0.05). The average BCVA was significantly higher at 1, 3, and 6 months after than before the injection (<jats:italic>P<\/jats:italic> &amp;lt; 0.05 each). The average central retinal thickness was significantly lower at 1, 3, and 6 months after than before the injection (<jats:italic>P<\/jats:italic> &amp;lt; 0.05 each). The number of injections was 3.08 \u00b1 0.27 at the last follow-up. No adverse reactions, such as endophthalmitis, retinal detachment, or thrombus, were observed in any patient after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Multiple intravitreal injections of conbercept can improve the BCVA and reduce macular edema in patients with BRVO and have no significant effect on the cornea.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1595543","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:26:10Z","timestamp":1750829170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of multiple intravitreal injections of conbercept on the cornea in patients with branch retinal vein occlusion-induced macular edema"],"prefix":"10.3389","volume":"12","author":[{"given":"Gaixia","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiehui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"627674","DOI":"10.1155\/2015\/627674","article-title":"Anti-VEGF therapy and the retina: An update.","volume":"2015","author":"Tah","year":"2015","journal-title":"J Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40123-018-0149-3","article-title":"Real-world results of switching treatment from ranibizumab to aflibercept in macular oedema secondary to branch retinal vein occlusion.","volume":"7","author":"Konidaris","year":"2018","journal-title":"Ophthalmol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1445-5994.2008.01720.x","article-title":"Retinal vein occlusion: An approach to diagnosis, systemic risk factors and management.","volume":"38","author":"Yau","year":"2009","journal-title":"Intern Med J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","article-title":"Natural history of branch retinal vein occlusion: An evidence-based systematic review.","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: An evidence-based systematic review.","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study.","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12886-020-01494-x","article-title":"Intravitreal conbercept for branch retinal vein occlusion induced macular edema: One initial injection versus three monthly injections.","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/11206721241255721","article-title":"Immediate response to intravitreal treatment for macular edema due to diabetes and retinal vein occlusion.","volume":"35","author":"Ratra","year":"2024","journal-title":"Eur J Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e824","DOI":"10.1016\/j.jcjo.2024.01.016","article-title":"Branch retinal vein occlusion treated with anti-VEGF: To switch or not to switch?","volume":"59","author":"Shor","year":"2024","journal-title":"Can J Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/ICO.0b013e31818b8be0","article-title":"Evaluation of cytotoxic effects of bevacizumab on human corneal cells.","volume":"28","author":"Chalam","year":"2009","journal-title":"Cornea."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4928905","DOI":"10.1155\/2020\/4928905","article-title":"Effect of repeated intravitreal ranibizumab and aflibercept injections on the cornea in patients with age-related macular degeneration.","volume":"2020","author":"Urban","year":"2020","journal-title":"J Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12886-018-0978-9","article-title":"Effects of ranibizumab (Lucentis\u00ae) and bevacizumab (Avastin\u00ae) on human corneal endothelial cells.","volume":"18","author":"Merz","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.2337\/db07-0982","article-title":"Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas.","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes."},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/aos.12956","article-title":"Effects of focal\/grid laser treatment on the central visual field in diabetic macular oedema: A 2-year follow-up study.","volume":"94","author":"Tababat-Khani","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/s0161-642030849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. the central vein occlusion study group M report.","volume":"102","year":"1995","journal-title":"Ophthalmology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/jcm13092490","article-title":"Visual acuity and retinal thickness and sensitivity after intravitreal ranibizumab injection for macular edema in branch retinal vein occlusion.","volume":"13","author":"Nonaka","year":"2024","journal-title":"J Clin Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/ojo.ojo_328_22","article-title":"Treatment outcomes for maculopathy secondary to retinal vein occlusion in Afghanistan.","volume":"17","author":"Delsoz","year":"2024","journal-title":"Oman J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9046781","DOI":"10.1155\/2020\/9046781","article-title":"Evaluation of microvascular structure changes after conbercept treatment on macular edema secondary to retinal vein occlusion.","volume":"2020","author":"Song","year":"2020","journal-title":"Biomed Res Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.18240\/ijo.2022.11.12","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China.","volume":"15","author":"Zhu","year":"2022","journal-title":"Int J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jcpt.12551","article-title":"Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis.","volume":"42","author":"Qian","year":"2017","journal-title":"J Clin Pharm Ther."},{"key":"B23","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00417-013-2505-2","article-title":"Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.","volume":"252","author":"Wang","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B25","first-page":"368","article-title":"Effect of repeated intravitreal aflibercept injections on the cornea in patients with macular edema.","volume":"41","author":"Lin","year":"2021","journal-title":"Rec Adv Ophthalmol."},{"key":"B26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/15569527.2019.1616749","article-title":"Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.","volume":"38","author":"Arslan","year":"2019","journal-title":"Cutan Ocul Toxicol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2473234","DOI":"10.1155\/2016\/2473234","article-title":"A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy.","volume":"2016","author":"Yang","year":"2016","journal-title":"J Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12886-021-02174-0","article-title":"Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.2147\/IJGM.S373015","article-title":"Effect of conbercept treatment on macular edema and microvascular structure in eyes with retinal vein occlusions.","volume":"15","author":"Ding","year":"2022","journal-title":"Int J Gen Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e24774","DOI":"10.1002\/jcla.24774","article-title":"Conbercept improves macular microcirculation and retinal blood supply in the treatment of nonischemic branch retinal vein occlusion macular edema.","volume":"36","author":"Huang","year":"2022","journal-title":"J Clin Lab Anal."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.18240\/ijo.2023.07.21","article-title":"Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: A meta-analysis.","volume":"16","author":"Xing","year":"2023","journal-title":"Int J Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/ICO.0b013e3181ca33d2","article-title":"Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration.","volume":"29","author":"P\u00e9rez-Rico","year":"2010","journal-title":"Cornea."},{"key":"B33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.18240\/ijo.2022.03.18","article-title":"Efficacy of intravitreal conbercept injection on short\u2013 and long-term macular edema in branch retinal vein occlusion.","volume":"15","author":"Bai","year":"2022","journal-title":"Int J Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1177\/0300060518819613","article-title":"Short-term effect of intravitreal conbercept injection on major and macular branch retinal vein occlusion.","volume":"47","author":"Tao","year":"2019","journal-title":"J Int Med Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1595543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:26:11Z","timestamp":1750829171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1595543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":34,"alternative-id":["10.3389\/fmed.2025.1595543"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1595543","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"article-number":"1595543"}}